ImmunityBio Inc News - IBRX

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other...

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment PR Newswire FREMONT...

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the...

Form 8-K - Current report

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

High responder rate associated with a duration of response ranging as long as 54 months in QUILT-3.032 with 100 patients enrolled Updated data...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ImmunityBio Reports Third-Quarter 2024 Financial Results

ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code...

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors First natural killer cell-based cellular therapy...

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London...

Monksdream 14 hours ago

IBRX under $3

👍️0

westjtter 1 day ago

Anyone know if the $100 million in stock offering(33 mil shares) is now complete? This was originally to close around Dec 12th....also there was an option for an additional 5 million shares to the underwriters for 30 more days after closing.

Just curious as to who were the buyers of this stock? I would hope and think once this offering closes the share price should slowly start to head higher again.

👍️0

Bourbon_on_my_cornflakes 1 week ago

Sub $2.50 next week?
Year-end selling killing this one...or is it something else?

👍️0

jondoeuk 4 weeks ago

This will be interesting, but we know that cancer cells are able to develop multiple mechanisms that enable the evasion of NKs. These mechanisms are likely the reason why NK based therapies show only limited success in clinic trials. Here is just one mechanism (that was recently found) https://www.cell.com/cell/abstract/S0092-8674(24)00355-6

https://x.com/DrPatSoonShiong/status/1861433583186932141

👍️0

jondoeuk 4 weeks ago

A new paper on anti-HER2 CAR-NKs (+/- anti-PD-1) https://academic.oup.com/neuro-oncology/article/26/Supplement_8/viii85/7890050

👍️0

Bourbon_on_my_cornflakes 1 month ago

what do you think is the biggest factor for the recent rise?

👍️0

glenn1919 2 months ago

IBRX........................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783

👍️0

TrendTrade2016 2 months ago

IBRX ROCKET SHIP

👍️0

TrendTrade2016 2 months ago

IBRX PUSH PUSH PUSH

👍️0

glenn1919 2 months ago

IBRX...................................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783

👍️0

TrendTrade2016 2 months ago

jondoeuk 2 months ago

A case report. From it: ''Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written.'' https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae267/7814737

👍️ 2

aBeezlee 3 months ago

$2 would be great. We'll see.

👍️0

Bourbon_on_my_cornflakes 3 months ago

Wait until it hits $2.50

Hold!

👍️0

axelvento 3 months ago

bouncer$ ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

https://immunitybio.com/immunitybio-presents-positive-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy/

👍️0

Monksdream 4 months ago

IBRX under $4

👍️0

Bourbon_on_my_cornflakes 4 months ago

Down and down, is approval for other cancer expected in June dead?

👍️0

Bourbon_on_my_cornflakes 4 months ago

Why did IBRX tank so badly in mid August?

👍️0

Bourbon_on_my_cornflakes 4 months ago

IBRX at $4

Wow. Where is the pancreatic cancer approval expected in June?

👍️0

Monksdream 5 months ago

IBRX under $6

👍️0

Monksdream 6 months ago

IBRX under $10

👍️0

jgrabar 6 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ImmunityBio, Inc. (IBRX)
See https://grabarlaw.com/the-latest/immunitybio-shareholder-investigation/

👍️0

tw0122 6 months ago

09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.

👍️0

Bourbon_on_my_cornflakes 6 months ago

Any thoughts on how much revenue FDA approval will bring?

👍️0

wrk_SATX 7 months ago

Still +54M shares short and time is ticking. 80% inside ownership with a small float.

👍️0

saigai 7 months ago

up and down.. no problem.. ima staying put

👍️0

saigai 7 months ago

we know there is a very large short position here.. i think that since the earnings post yesterday and the reaction to it that there is now very little reason to stay short,,lets see that spike

👍️0

carldfw 8 months ago

Pancreatic Cancer next!!
I like Oncolytics on that list

👍️0

Tahoe2468 8 months ago

7. ImmunityBio Inc (NASDAQ:IBRX)
Float Shorted: 40.37%

With over 53 million of its shares shorted, ImmunityBio Inc’s (NASDAQ:IBRX) short interest stands at 40.37% as of April 8.

👍️0

jondoeuk 8 months ago

From Jan 19, 2023: ''ImmunityBio also announced that it held two productive Type B meetings with the FDA in December. The first was to present the recent data and obtain guidance toward a registration pathway in metastatic pancreatic cancer.'' https://www.businesswire.com/news/home/20230119005337/en/ImmunityBio-Announces-Presentation-at-ASCO-GI-2023-of-Fully-Enrolled-Trial-in-Third-Line-and-Greater-Pancreatic-Cancer-and-Update-on-FDA-Type-B-Meetings-Regarding-Paths-to-Registration

What happened?

👍️0

jondoeuk 8 months ago

Nothing listed in the pipeline.

👍️0

Tahoe2468 8 months ago

Pancreatic Cancer next!! WOW!!

https://www.prnewswire.com/news-releases/biotechs-role-in-addressing-the-pancreatic-cancer-emergency-302089052.html

👍️0

TrendTrade2016 8 months ago

IBRX monster bio on the weekly break out

👍️0

MiamiGent 8 months ago

IBRX Friday Close $7.35+$2.24 (+43.84%)

This morning Pre-Mkt
Bid x Size
$8.13 x 2
Ask x Size
$8.20 x 212
Volume
862,349
90 Day Avg. Vol.
4,851,152

Bona fide squeeze underway. Millions of shares short are trapped.

👍️ 1

carldfw 8 months ago

Pancreatic will be even better!!In January 2023, ImmunityBio announced that it held two meetings with the FDA in December 2022 to present data and get guidance on a registration pathway for metastatic
pancreatic cancer
. The company's combination immunotherapy
, Nant Cancer Vaccine, has shown potential effectiveness in pancreatic cancer, more than doubling median overall survival (OS) compared to historical OS.

👍️0

martind18 8 months ago

That’s because IHUB is for pump and dumps.

👍️ 2

Atom Smasher 8 months ago

Good ole ihub. We have a REAL company here with a remarkable game changing cancer drug whose stock price will not only explode but retain it's stock price and no one here is even talking about it. As per my experience here several years ago.......everyone here is only interested in shells and scam companies. What a shame. That's fine. I'll be making bank. Join me if you want.......or don't. I'm not selling till it's somewhere above 40

👍️ 2

Monksdream 8 months ago

This a simple bar/volume with 60-minute intervals

The stock is actually trading counter to a recent bearish trend for most tickers according my bit of DD from the Barchart website that would be considered med tech companies
This a link for the sector that is made up 459 tickers
https://www.barchart.com/stocks/quotes/IBRX/competitors?quoteSectors=-MEBI&viewName=main&orderBy=weightedAlpha&orderDir=desc

I have a free membership so I can use the flipcharts function for the past six months of price discovery
One can observe from the sector graph at the top of the page the best time to buy any old med stock was last November
The best time to sell was at the peak last March which isn’t that long ago
I can observe the same recurring pattern in the more than 200 tickers I flipped through

👍️0

Atom Smasher 8 months ago

https://www.barchart.com/stocks/quotes/IBRX/opinion

👍️0

Monksdream 8 months ago

IBRX in the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️ 1

axelvento 8 months ago

https://twitter.com/YahooFinance/status/1782859110771278268

martind18 8 months ago

FDA approval!

https://www.investorsobserver.com/news/qm-news/8088196297645818

👍️0

axelvento 9 months ago

The FDA has accepted the BLA resubmission and will now review the therapy. It has set a Prescription Drug User Fee Act (PDUFA) date of 23 April 2024.

👍️0

Monksdream 9 months ago

IBRX chart

👍️0

Spideyboy 10 months ago

Just curious, having read this article from June 2022, what makes us think that they will get approval for Antikva.

My concern just stems from the bottom of the article stating.

"Other drugs are in late-stage trials in combination with BCG for the same patient population, including AstraZeneca’s Imfinzi (durvalumab) and Sesen Bio’s Vicinium (oportuzumab monatox). The FDA previously rejected Sesen Bio’s BLA for the treatment of BCG-unresponsive patients, citing multiple issues, including a lack of randomised data comparing Vicinium with an investigator’s choice of intravesical chemotherapy."
https://www.pharmaceutical-technology.com/analyst-comment/immunitybio-first-marketed-drug/?cf-view

There is no comparator in the Antikva trial with any intravesical chemotherapy either, or against anything for that matter. As it's open-label single arm trial, with only Antikva being used. Will this be enough for FDA approval?

I know the prior CRL didn't mention anything about this, but that doesn't mean it isn't a potential issue?

Looking to be convinced wrong on the above :)

👍️0

Monksdream 10 months ago

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️0

brogers_1 11 months ago

Research tool: https://tradingtimeline.com/ibrx.html

👍️0

martind18 12 months ago

https://www.oberlandcapital.com/news-post/immunitybio-announces-320-million-investment-by-oberland-capital/

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ImmunityBio Inc (IBRX)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

IBRX News

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Form 8-K - Current report

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ImmunityBio Reports Third-Quarter 2024 Financial Results

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

ImmunityBio to Participate in the Jefferies London Healthcare Conference

IBRX Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ImmunityBio Inc (IBRX) News

ImmunityBio Inc (IBRX)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

IBRX News

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Form 8-K - Current report

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ImmunityBio Reports Third-Quarter 2024 Financial Results

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

ImmunityBio to Participate in the Jefferies London Healthcare Conference

IBRX Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free